Myeloid Bias in the Bone Marrow of Septic Patients and Its Correlation With Disease Severity and Prognosis: A Single-Center, Prospective Cohort Study

Myeloid Bias in the Bone Marrow of Septic Patients

Sepsis remains a leading cause of critical illness worldwide, yet the underlying mechanisms driving its profound and persistent immune dysfunction are incompletely understood. The bone marrow, as the birthplace of all immune cells, plays a central role in orchestrating systemic immune responses. Emerging evidence from animal models suggests that sepsis triggers emergency myeloid-biased hematopoiesis in the bone marrow, characterized by expansion of myeloid progenitors and myeloid-derived suppressor cells (MDSCs) at the expense of lymphoid and erythroid lineages. This bone marrow remodeling precedes peripheral immune alterations and may represent the initiating event of sepsis-induced immunosuppression. However, direct clinical evidence in humans is scarce. This prospective, single-center cohort study aims to systematically characterize bone marrow hematopoietic remodeling in patients with septic shock, compared to critically ill non-septic patients and healthy volunteers, and to determine whether the degree of myeloid lineage bias correlates with disease severity, immunosuppression, and adverse clinical outcomes.

This study will enroll three cohorts. Bone marrow aspirates and peripheral blood samples will be collected at 48-72 hours post-enrollment for flow cytometric immunophenotyping of hematopoietic stem/progenitor cells, MDSC subsets, and PD-L1 expression, as well as cytokine profiling and exploratory single-cell transcriptomics. Rectal swabs will be collected synchronously for 16S rRNA sequencing and untargeted metabolomics to investigate the association between gut microbiota, microbial metabolites, and bone marrow myeloid skewing, testing the gut-bone marrow-immune axis hypothesis. Clinical severity (SOFA/APACHE II), secondary infections, and 90-day mortality will be assessed to evaluate prognostic value. By integrating bone marrow hematopoiesis, gut microbiome, and clinical outcomes, this study seeks to provide novel mechanistic insights into sepsis-induced immunoparalysis and identify potential biomarkers or therapeutic targets for immune restoration.

Study Overview

• Status: Not yet recruiting
• Conditions: Sepsis; Septic Shock
• Intervention / Treatment: Procedure: Bone marrow aspirate collection

• Study Type: Observational
• Enrollment (Estimated): 45

Contacts and Locations

• Study Contact: Name: Zhang Jiancheng, MD, PhD; Phone Number: +8613554105815; Email: zhjcheng1@126.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

This prospective single-centre study will enrol three independent cohorts: (1) adult ICU patients (18-80 years) with sepsis per Sepsis-3.0, admitted for 48-72 hours with an expected ICU stay ≥7 days; (2) adult ICU patients with non-infectious critical illnesses (e.g., severe pancreatitis, major trauma, post-major surgery, acute cerebrovascular events) who do not meet Sepsis-3.0 criteria; and (3) healthy community volunteers with no acute/chronic diseases and normal blood counts. All participants (or legally authorised representatives for incapacitated patients) must provide written informed consent, with re-consent obtained once patients regain capacity. Common exclusions include primary haematological disorders, active malignancy, immunosuppression, recent transfusion, severe chronic organ dysfunction, local contraindications to bone marrow puncture, pregnancy, and concurrent participation in other interventional trials.

Description

1. Inclusion Criteria

(1) Sepsis-Associated Critical Illness Cohort

• Age 18-80 years, both genders;
• Meets the Sepsis-3.0 criteria: confirmed or suspected infection with an acute increase in SOFA score of ≥2 points;
• Admitted to the intensive care unit (ICU) for 48-72 hours at the time of enrolment;
• Expected ICU length of stay ≥7 days;

• Written informed consent provided by the patient or their legally authorized representative.

  (2) Non-Septic Critical Illness Cohort

• Age 18-80 years, both genders;
• Admitted to the ICU for 48-72 hours with a diagnosis of non-infectious critical illness, including but not limited to: (a) severe acute pancreatitis; (b) major trauma (Injury Severity Score ≥16); (c) post-major surgery (e.g., cardiovascular surgery, hepatectomy); (d) acute cerebrovascular disease (ischaemic stroke, intracerebral haemorrhage); (e) other critical conditions requiring ICU support;
• Expected ICU length of stay ≥7 days;

• Written informed consent provided by the patient or their legally authorized representative.

  (3) Healthy Volunteer Control Cohort

• Age 18-80 years, both genders.
• No acute or chronic medical history; recent health check-up results are normal.
• Normal complete blood count: white blood cell count, haemoglobin, and platelet count within the normal reference ranges;

• Willing and able to provide written informed consent.

  2. Exclusion Criteria

  (1) Sepsis-Associated Critical Illness Cohort

• Haematological disorders: previous or current primary haematological diseases affecting bone marrow haematopoiesis, including leukaemia, myelodysplastic syndromes, aplastic anaemia, multiple myeloma, lymphoma, etc;
• Active malignancy or receipt of chemotherapy/radiotherapy within the past 3 years;
• Immunosuppressed state: (a) use of immunosuppressive agents within the past 3 months (including glucocorticoids ≥0.5 mg/kg/day for ≥2 weeks); (b) history of solid organ or haematopoietic stem cell transplantation; (c) HIV infection or AIDS; (d) congenital immunodeficiency;
• Blood transfusion or bone marrow transplantation within the past 3 months;
• Severe chronic organ dysfunction: (a) Child-Pugh Class C liver disease; (b) end-stage renal disease (eGFR <30 mL/min) without regular dialysis;
• Abnormalities at the puncture site: infection, rash, trauma, or anatomical deformity at the posterior superior iliac spine;
• Pregnancy or breastfeeding;
• Moribund state with expected survival <24 hours;
• Participation in another interventional clinical trial within 3 months before or at enrolment;

• Refusal to sign informed consent by the patient or legal representative.

  (2) Non-Septic Critical Illness Cohort

• Evidence of infection: confirmed or suspected active infection (including pneumonia, intra-abdominal infection, urinary tract infection, bloodstream infection, etc.) within 48 hours of ICU admission;

• All other exclusion criteria listed for the Sepsis-Associated Critical Illness Cohort (items 1-10) apply.

  (3) Healthy Volunteer Control Cohort

• History of infection within the past 1 month;
• Abnormalities at the puncture site: infection, rash, trauma, or anatomical deformity at the posterior superior iliac spine;
• Pregnancy or breastfeeding.

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Sepsis-Associated Critical Illness Cohort; Patients admitted to the intensive care unit (ICU) with a confirmed or highly suspected infection and meeting the Sepsis-3 criteria (an acute change in Sequential Organ Failure Assessment [SOFA] score ≥ 2 points in the presence of infection).	Procedure: Bone marrow aspirate collection; Bone marrow aspiration was performed at the posterior superior iliac spine under local anesthesia 24-48 hours after enrollment. Using a standard aspirate needle and strict aseptic technique, approximately 2-3 mL of bone marrow aspirate was collected.
Non-Septic Critical Illness Cohort; Critically ill patients admitted to the same ICU with an acute life-threatening condition that is not attributed to infection. Typical etiologies include severe trauma, major elective or emergency surgery (e.g., abdominal, or neurosurgical procedures), acute pancreatitis, or massive haemorrhage, all without any clinical or microbiological evidence of infection at enrolment.	Procedure: Bone marrow aspirate collection; Bone marrow aspiration was performed at the posterior superior iliac spine under local anesthesia 24-48 hours after enrollment. Using a standard aspirate needle and strict aseptic technique, approximately 2-3 mL of bone marrow aspirate was collected.
Healthy Volunteer Control Cohort; Community-dwelling adults with no acute or chronic medical conditions that could affect haematopoiesis or immune function. They are recruited from the same geographical region and during the same calendar period to minimise seasonal and demographic biases.	Procedure: Bone marrow aspirate collection; Bone marrow aspiration was performed at the posterior superior iliac spine under local anesthesia 24-48 hours after enrollment. Using a standard aspirate needle and strict aseptic technique, approximately 2-3 mL of bone marrow aspirate was collected.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage and Absolute Count of Hematopoietic Stem Cells (HSCs) in Bone Marrow	HSCs are defined as Lin- CD34⁺ CD38- CD90⁺ CD45RA- cells. The outcome is measured as both (a) the percentage among total bone marrow nucleated cells, and (b) the absolute count per 10⁶ total bone marrow nucleated cells. Comparison is made between the sepsis-associated critical illness cohort and the two control groups (critically ill non-septic cohort and healthy cohort).	Between 48 and 72 hours after enrollment (preferably day 3)
Percentage and Absolute Count of Common Myeloid Progenitors (CMPs) in Bone Marrow	CMPs are defined as Lin- CD34⁺ CD38⁺ CD123⁺ CD45RA- cells. The outcome is measured as both (a) the percentage among total bone marrow nucleated cells, and (b) the absolute count. Comparison is made between the sepsis cohort and the two control groups.	Between 48 and 72 hours after enrollment (preferably day 3)
Percentage and Absolute Count of Granulocyte-Monocyte Progenitors (GMPs) in Bone Marrow	GMPs are defined as Lin- CD34⁺ CD38⁺ CD123⁺ CD45RA⁺ cells. The outcome is measured as both (a) the percentage among total bone marrow nucleated cells, and (b) the absolute count. This is a core indicator of myeloid lineage expansion. Comparison is made between the sepsis cohort and the two control groups.	Between 48 and 72 hours after enrollment (preferably day 3)
Percentage and Absolute Count of Megakaryocyte-Erythroid Progenitors (MEPs) in Bone Marrow	MEPs are defined as Lin- CD34⁺ CD38⁺ CD123- CD45RA- cells. The outcome is measured as both (a) the percentage among total bone marrow nucleated cells, and (b) the absolute count. This indicator reflects erythroid/megakaryocytic lineage suppression. Comparison is made between the sepsis cohort and the two control groups.	Between 48 and 72 hours after enrollment (preferably day 3)
Percentage and Absolute Count of Common Lymphoid Progenitors (CLPs) in Bone Marrow	CLPs are defined as Lin- CD34⁺ CD38⁺ CD127⁺ cells. The outcome is measured as both (a) the percentage among total bone marrow nucleated cells, and (b) the absolute count. This indicator reflects lymphoid lineage suppression. Comparison is made between the sepsis cohort and the two control groups.	Between 48 and 72 hours after enrollment (preferably day 3)
GMP-to-CLP Ratio and Absolute Differential Count Index in Bone Marrow (Primary Composite Index)	The primary composite index of myeloid lineage bias consists of two parallel metrics: (a) the GMP-to-CLP ratio, calculated as (percentage of GMPs)/(percentage of CLPs); and (b) the absolute differential index, calculated as (absolute count of GMPs)/(absolute count of CLPs). Both metrics quantify myeloid-versus-lymphoid lineage skewing. A higher value indicates greater myeloid bias. Comparison is made between the sepsis cohort and the two control groups.	Between 48 and 72 hours after enrollment (preferably day 3)
Percentage and Absolute Count of PMN-MDSCs in Bone Marrow	Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are defined as CD45⁺ CD11b⁺ CD14- CD15⁺ CD33⁺ HLA-DR-/low cells. The outcome is measured as both (a) the percentage among total bone marrow nucleated cells, and (b) the absolute count. Comparison is made between the sepsis cohort and the two control groups.	Between 48 and 72 hours after enrollment (preferably day 3)
Percentage and Absolute Count of M-MDSCs in Bone Marrow	Monocytic myeloid-derived suppressor cells (M-MDSCs) are defined as CD45⁺ CD11b⁺ CD14⁺ HLA-DR-/low CD15- cells. The outcome is measured as both (a) the percentage among total bone marrow nucleated cells, and (b) the absolute count. Comparison is made between the sepsis cohort and the two control groups.	Between 48 and 72 hours after enrollment (preferably day 3)
PD-L1 Expression Level and PD-L1⁺ Absolute Count on Bone Marrow MDSCs	PD-L1 (programmed death-ligand 1) expression on both PMN-MDSCs and M-MDSCs is measured as three parallel metrics: (a) the percentage of PD-L1⁺ cells within each MDSC subset; (b) the median fluorescence intensity (MFI) of PD-L1 on these cells; and (c) the absolute count of PD-L1⁺ PMN-MDSCs and PD-L1⁺ M-MDSCs. These indicators reflect the immunosuppressive functional burden of MDSCs. Comparison is made between the sepsis cohort and the two control groups.	Between 48 and 72 hours after enrollment (preferably day 3)
Percentage and Absolute Count of T Cells in Bone Marrow	T cells are defined as CD45⁺ CD56- CD3⁺ cells. The outcome is measured as both (a) the percentage among total bone marrow nucleated cells, and (b) the absolute count. Comparison is made between the sepsis cohort and the two control groups.	Between 48 and 72 hours after enrollment (preferably day 3)
Percentage and Absolute Count of NK Cells in Bone Marrow	Natural killer (NK) cells are defined as CD45⁺ CD3- CD56⁺ cells. The outcome is measured as both (a) the percentage among total bone marrow nucleated cells, and (b) the absolute count. Comparison is made between the sepsis cohort and the two control groups.	Between 48 and 72 hours after enrollment (preferably day 3)
Percentage and Absolute Count of Monocytes in Bone Marrow	Monocytes are defined as CD45⁺ CD3- CD56- HLA-DR⁺ CD14⁺ CD15- cells. The outcome is measured as both (a) the percentage among total bone marrow nucleated cells, and (b) the absolute count. Comparison is made between the sepsis cohort and the two control groups.	Between 48 and 72 hours after enrollment (preferably day 3)
Percentage and Absolute Count of Neutrophils in Bone Marrow	Neutrophils are defined as CD45⁺ CD3- CD56- CD11b⁺ CD14- CD15⁺ cells. The outcome is measured as both (a) the percentage among total bone marrow nucleated cells, and (b) the absolute count. Comparison is made between the sepsis cohort and the two control groups.	Between 48 and 72 hours after enrollment (preferably day 3)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Correlation Between Bone Marrow GMP-to-CLP Ratio (Percentage and Absolute) and SOFA score	Correlation between the baseline bone marrow GMP-to-CLP composite indices (both ratio based on percentages and ratio based on absolute counts) and SOFA score. SOFA score is calculated at enrollment and on days 1, 3, and 5. Correlation analyzed using Spearman correlation coefficients.	Baseline (bone marrow at 48-72 hours) and days 1, 3, 5, 7 (severity scores)
Correlation Between Bone Marrow GMP-to-CLP Ratio (Percentage and Absolute) and APACHE II score	Correlation between the baseline bone marrow GMP-to-CLP composite indices (both ratio based on percentages and ratio based on absolute counts) and APACHE II score. APACHE II score is calculated at enrollment and on days 1, 3, and 5. Correlation analyzed using Spearman correlation coefficients.	Baseline (bone marrow at 48-72 hours) and days 1, 3, 5, 7 (severity scores)
Association Between Bone Marrow Myeloid Lineage Bias (Percentages and Absolute Counts) and 90-Day Secondary Infection Rate	Evaluate whether the degree of baseline bone marrow myeloid lineage bias (measured by GMP-to-CLP ratio, percentage and absolute counts of PMN-MDSCs and M-MDSCs, and absolute count of PD-L1⁺ MDSCs) is independently associated with the occurrence of secondary infections within 90 days. Secondary infection is defined as a new infectious episode occurring ≥48 hours after enrollment, diagnosed by positive culture and/or clinical criteria requiring new antibiotic therapy. Logistic regression will be used, adjusting for baseline SOFA and APACHE II scores.	From enrollment through 90-day follow-up
Bone Marrow Myeloid Lineage Bias (Percentages and Absolute Counts) as Predictors of 90-Day All-Cause Mortality	Evaluate the predictive value of baseline bone marrow cellular indices (GMP-to-CLP ratio, percentage and absolute counts of PMN-MDSCs and M-MDSCs, and absolute count of PD-L1⁺ MDSCs) for 90-day all-cause mortality. Survival analysis using Kaplan-Meier curves with Log-rank tests, and Cox proportional hazards regression calculating hazard ratios adjusted for age, SOFA score, and APACHE II score.	From enrollment through 90-day follow-up
Association Between Bone Marrow Myeloid Lineage Bias (Percentages and Absolute Counts) and ICU / In-Hospital Mortality	Evaluate the association between baseline bone marrow myeloid lineage bias indices (percentage and absolute counts of progenitor and MDSC subsets) and short-term mortality endpoints, including ICU mortality and in-hospital mortality. Logistic regression will be used to calculate odds ratios adjusted for baseline severity scores.	From enrollment through hospital discharge (up to 90 days)
Correlation Between Bone Marrow MDSC Absolute Counts and Peripheral Blood Lymphocyte Absolute Counts	Assess the correlation between bone marrow PMN-MDSC and M-MDSC frequencies and absolute counts (along with their PD-L1 expression) and peripheral blood lymphocyte subset absolute counts per μL (and percentages). Peripheral blood immunophenotyping includes: CD3⁺ total T cells, CD3⁺CD4⁺ helper T cells, CD3⁺CD8⁺ cytotoxic T cells, CD3-CD16⁺CD56⁺ NK cells, and CD19⁺ B lymphocytes. This provides mechanistic evidence linking the absolute burden of bone marrow MDSCs to the severity of systemic lymphopenia-a hallmark of sepsis-induced immunosuppression.	Baseline (bone marrow and peripheral blood at 48-72 hours; peripheral blood also on days 1, 5, 7 for longitudinal correlation)
Association Between Bone Marrow Myeloid Progenitor Absolute Counts and Peripheral Blood Cytokine Profile	Association between baseline bone marrow absolute counts of myeloid progenitors (GMPs, total MDSCs) and peripheral blood serum cytokine levels (measured in pg/mL). Serum cytokines are measured by multiplex assay and include: IL-2, IL-4, IL-6, IL-10, IL-17A, IFN-γ, and TNF-α. Inflammatory markers CRP and PCT are measured on days 1, 3, 5, and 7.	Baseline (bone marrow and peripheral blood at 48-72 hours); CRP/PCT on days 1, 3, 5, 7
Longitudinal Dynamics of Peripheral Blood Lymphocyte and MDSC Percentages and Absolute Counts During the First Week	Track the dynamic changes in peripheral blood percentages and absolute counts per μL of CD3⁺ T cells (and CD4⁺/CD8⁺ subsets), CD19⁺ B cells, CD3-CD16⁺CD56⁺ NK cells, PMN-MDSCs, and M-MDSCs on days 1, 3, 5, and 7 after enrollment. Day 1 is the early systemic immune baseline preceding peak bone marrow remodeling (day 3); day 3 coincides with the primary aspiration for direct cross-sectional correlation; days 5 and 7 track post-remodeling trajectories. This temporal hierarchy tests whether bone marrow absolute myeloid burden drives subsequent peripheral immunosuppression.	Days 1, 3, 5, 7 post-enrollment (peripheral blood)
Bone Marrow Microenvironment Cytokine and Chemokine Profile (Concentration)	Cytokine and chemokine concentrations (pg/mL) in bone marrow supernatant obtained from the aspirate, measured by ELISA or Luminex multiplex assay. Analytes include: G-CSF, GM-CSF, IL-6, IL-1β, TNF-α, IL-10, CXCL1, CXCL12, and CCL2. Levels are compared across the three cohorts to identify sepsis-specific bone marrow microenvironment alterations that may drive the myeloid lineage bias and MDSC accumulation.	Baseline (bone marrow supernatant at 48-72 hours)
Exploratory Single-Cell Transcriptomic Profiling of Bone Marrow Hematopoietic Cells	Single-cell RNA sequencing (scRNA-seq) on bone marrow mononuclear cells from a subset of sepsis patients and healthy controls to identify differentially expressed genes and transcriptional pathways associated with myeloid lineage bias. Includes differential expression analysis and pathway enrichment (e.g., IFN signaling, STAT3, CEBPB, emergency granulopoiesis signatures).	Baseline (bone marrow aspirate at 48-72 hours)
Correlation Between Gut Microbiota Alpha Diversity and Bone Marrow Myeloid Lineage Bias	Assess the correlation between gut microbiota alpha diversity indices (Shannon index, Simpson index, Chao1 index) and bone marrow myeloid lineage bias indices, including: GMP-to-CLP ratio, percentage and absolute counts of PMN-MDSCs and M-MDSCs, PD-L1 expression on MDSCs, and HSC/CMP/MEP/CLP counts.	At 48-72 hours post-enrollment (rectal swab and bone marrow synchronized)
Correlation Between Key Dysbiotic Gut Bacterial Taxa and Bone Marrow Myeloid Lineage Bias	Identify key gut bacterial taxa that are significantly altered in sepsis and assess their correlation with bone marrow myeloid lineage bias indices, including: GMP-to-CLP ratio, percentage and absolute counts of PMN-MDSCs and M-MDSCs, PD-L1 expression on MDSCs, and HSC/CMP/MEP/CLP counts.	At 48-72 hours post-enrollment (rectal swab and bone marrow synchronized)
Association Between Gut Microbiota-Derived Metabolites and Bone Marrow Myeloid Lineage Bias	Identify gut microbiota-derived metabolites associated with bone marrow myeloid lineage bias using untargeted metabolomics (LC-MS/MS) on rectal swab samples. Metabolite profiles are correlated with bone marrow myeloid lineage bias indices, including: GMP-to-CLP ratio, percentage and absolute counts of PMN-MDSCs and M-MDSCs, PD-L1 expression on MDSCs, and HSC/CMP/MEP/CLP counts.	Rectal swab and bone marrow at 48-72 hours post-enrollment (synchronized)

Collaborators and Investigators

• Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Study record dates

Study Major Dates

• Study Start (Estimated): July 15, 2026
• Primary Completion (Estimated): June 15, 2027
• Study Completion (Estimated): December 30, 2027

Study Registration Dates

• First Submitted: June 18, 2026
• First Submitted That Met QC Criteria: June 18, 2026
• First Posted (Actual): June 24, 2026

Study Record Updates

• Last Update Posted (Actual): June 24, 2026
• Last Update Submitted That Met QC Criteria: June 18, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: Prognosis; Sepsis; Bone marrow; Myeloid bias
• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Systemic Inflammatory Response Syndrome; Inflammation; Shock; Pathological Conditions, Signs and Symptoms; Sepsis; Shock, Septic
• Other Study ID Numbers: ZJC202603

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No